HALIFAX, Nova Scotia and SPRING, Texas, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Scientists at Dalhousie University in Halifax, and Io Therapeutics, Inc. in Spring Texas, announced today collaborative publication of data from studies demonstrating effectiveness of the RXR agonist compound IRX4204 in reversing demyelination, and functionally restoring movement in the paralyzed legs of mice subjected to an autoimmune-mediated demyelinating model of human multiple sclerosis (MS). The research report titled: "Selective retinoid X receptor agonism promotes functional recovery and myelin repair in experimental autoimmune encephalomyelitis", G.D.S Kasheke, et al; was published in the December 21, 2024 edition of Acta Neuropathologica Communications.
IRX4204 selectively activates the retinoid X receptor (RXR). Given compelling links between RXR activation and increased myelin repair, the collaborating scientists employed IRX4204 to investigate the impact of RXR agonism on functional recovery in mice subjected to experimental autoimmune encephalomyelitis (EAE). EAE is a commonly used model of neuroinflammation in human MS. Machine learning was used to obtain highly sensitive and reliable measurements of hindleg movements for mice walking on a treadmill. IRX4204 not only blocked progressive loss of knee and ankle movements, but also reversed joint movement impairments in EAE mice. Biochemical, transcriptional and histological measurements in spinal cord supported that these gait improvements reflected increased axon survival, remyelination, and reduced inflammation. Using microglia, astrocytes and oligodendrocyte progenitor cells, additional data was obtained suggesting that IRX4204 acts on multiple glial subtypes to orchestrate myelin repair.
kAmv6@C86 $] #@36CED@?[ !9]s] :D E96 =625 D4:6?E:DE 7@C E96D6 DEF5:6D] w6 :D 2 !C@76DD@C :? E96 s6A2CE>6?ED @7 !DJ49:2ECJ 2?5 !92C>24@=@8J 2E s2=9@FD:6 &?:G6CD:EJ] w:D =23@C2E@CJ :D =@42E65 :? E96 qC2:? #6A2:C r6?EC6 2E s2=9@FD:6 &?:G6CD:EJ] sC] #@36CED@? DE2E65 "%96D6 C6DF=ED :?7@C> E96 5:D4@G6CJ @7 C6DE@C2E:G6 ?6FC2= E96C2A6FE:4D 7@C |$ 3J 56>@?DEC2E:?8 E92E D6=64E:G6 #)# 28@?:D> :D DF77:4:6?E 7@C 67764E:G6 >J6=:? C6A2:C] |@C6@G6C[ @FC 7:?5:?8D DFAA@CE E96 E96C2A6FE:4 A@E6?E:2= @7 x#)ca_c E@ AC@>@E6 7F?4E:@?2= ?6FC@=@8:4 C64@G6CJ :? |$[ 2 =@?8\D@F89E E96C2A6FE:4 @3;64E:G6 :? E96 |$ C6D62C49 4@>>F?:EJ]" k^Am kAm|2CE:? t] $2?56CD[ |]s][ r9:67 tI64FE:G6 ~77:46C @7 x@ %96C2A6FE:4D DE2E65 "%96 23:=:EJ @7 x#)ca_c E@ :?9:3:E 2?5 7F?4E:@?2==J C6A2:C 3C2:? 56>J6=:?2E:@?[ H9:=6 2=D@ :?9:3:E:?8 >:4C@8=:2\>65:2E65 3C2:? :?7=2>>2E:@? :? 2? |$ >@56= @A6?D @AA@CEF?:E:6D 7@C A@E6?E:2==J C6A2C2E:G6 EC62E>6?E @7 3C2:? 52>286 :? @E96C EJA6D @7 ?6FC@=@8:4 4@?5:E:@?D :? H9:49 56>J6=:?2E:@? 2?5 >:4C@8=:2= :?7=2>>2E:@? 2C6 56>@?DEC2E65 E@ A=2J A2E9@=@8:4 C@=6D] tI2>A=6D @7 DF49 4@?5:E:@?D :?4=F56 ?@C>2= 28:?8\C6=2E65 ?6FC@5686?6C2E:@?[ p=K96:>6C'D 5:D62D6[ !2C<:?D@?'D 5:D62D6[ EC2F>2E:4 :?;FCJ[ DEC@<6[ 2?5 D49:K@A9C6?:2] %96 4@>A2?J :D A=2??:?8 E@ 56G6=@A x#)ca_c 7@C >F=E:A=6 ?6CG@FD DJDE6> :?5:42E:@?D]"k^AmkAmp3@FE x@ %96C2A6FE:4Di x@ %96C2A6FE:4D[ x?4] :D 2 AC:G2E6=J 96=5 4@>A2?J 9625BF2CE6C65 :? $AC:?8[ %6I2D] |@C6 :?7@C>2E:@? @? x@ %96C2A6FE:4D 2?5 :ED AC@5F4E 56G6=@A>6?E AC@8C2>D :D 2G2:=23=6 @? E96 4@>A2?J'D H63 D:E6i k2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2l@Ix&6\0:Ee<x+%wqJ%$wvv#'Ir8xD_B54$9gvFedK)y78@4:p+xqH7A)8x(a7};"ed8~zAI5##F5%g<'~"*xz{HEq5"*G7bE*_GCDq5'Iy<lQ C6=lQ?@7@==@HQmHHH]:@\E96C2A6FE:4D]4@>k^2m]k^Am kAmu@CH2C5 {@@<:?8 $E2E6>6?EDi %9:D ?6H C6=62D6 4@?E2:?D Q7@CH2C5\=@@<:?8 DE2E6>6?EDQ H:E9:? E96 >62?:?8 @7 E96 D276 92C3@C AC@G:D:@?D @7 E96 &?:E65 $E2E6D !C:G2E6 $64FC:E:6D {:E:82E:@? #67@C> p4E @7 'hhd]k^AmkAmk^AmkAmk^AmkAmr@?E24E :?7@C>2E:@?i k2 9C67lQ>2:=E@i:?7@o:@\E96C2A6FE:4D]4@>Qm:?7@o:@\E96C2A6FE:4D]4@>k^2m k2 9C67lQ>2:=E@i>D2?56CDo:@\E96C2A6FE:4D]4@>Qm>D2?56CDo:@\E96C2A6FE:4D]4@>k^2m WgbaX ae_\ea_'k^Am